{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:50:52Z","timestamp":1783605052581,"version":"3.55.0"},"reference-count":125,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2018,5,26]],"date-time":"2018-05-26T00:00:00Z","timestamp":1527292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The influenza virus is one of a few viruses that is capable of rendering an otherwise healthy person acutly bedridden for several days. This impressive knock-out effect, without prodromal symptoms, challenges our immune system. The influenza virus undergoes continuous mutations, escaping our pre-existing immunity and causing epidemics, and its segmented genome is subject to reassortment, resulting in novel viruses with pandemic potential. The personal and socieoeconomic burden from influenza is high. Vaccination is the most cost-effective countermeasure, with several vaccines that are available. The current limitations in vaccine effectivness, combined with the need for yearly updating of vaccine strains, is a driving force for research into developing new and improved influenza vaccines. The lack of public concern about influenza severity, and misleading information concerning vaccine safety contribute to low vaccination coverage even in high-risk groups. The success of future influeza vaccines will depend on an increased public awarness of the disease, and hence, the need for vaccination\u2014aided through improved rapid diagnositics. The vaccines must be safe and broadly acting, with new, measurable correlates of protection and robust post-marketing safety studies, to improve the confidence in influenza vaccines.<\/jats:p>","DOI":"10.3390\/vaccines6020032","type":"journal-article","created":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T02:58:18Z","timestamp":1527562698000},"page":"32","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical Expectations for Better Influenza Virus Vaccines\u2014Perspectives from the Young Investigators\u2019 Point of View"],"prefix":"10.3390","volume":"6","author":[{"given":"Kristin G.-I.","family":"Mohn","sequence":"first","affiliation":[{"name":"Influenza Centre, Department of Clinical Science, University of Bergen, Bergen 5021, Norway"},{"name":"Emergency Care clinic, Haukeland University Hospital, Bergen 5021, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9918-3422","authenticated-orcid":false,"given":"Fan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Influenza Centre, Department of Clinical Science, University of Bergen, Bergen 5021, Norway"},{"name":"K.G. Jebsen Centre for Influenza Vaccine Research, Department of Clinical Science, University of Bergen, Bergen 5021, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,5,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1046\/j.1365-2672.2001.01492.x","article-title":"A history of influenza","volume":"91","author":"Potter","year":"2001","journal-title":"J. Appl. Microbiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","article-title":"Estimates of global seasonal influenza-associated respiratory mortality: A modelling study","volume":"391","author":"Iuliano","year":"2018","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3201\/eid0505.990507","article-title":"The economic impact of pandemic influenza in the United States: Priorities for intervention","volume":"5","author":"Meltzer","year":"1999","journal-title":"Emerg. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1016\/j.vaccine.2007.03.046","article-title":"The annual impact of seasonal influenza in the US: Measuring disease burden and costs","volume":"25","author":"Molinari","year":"2007","journal-title":"Vaccine"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4172\/2162-6359.1000443","article-title":"The cost of influenza disease burden in U.S. Population","volume":"6","author":"Rothman","year":"2017","journal-title":"Int. J. Econ. Manag. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6927","DOI":"10.1016\/j.vaccine.2012.08.036","article-title":"Perceptions matter: Beliefs about influenza vaccine and vaccination behavior among elderly white, black and hispanic americans","volume":"30","author":"Wooten","year":"2012","journal-title":"Vaccine"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Cheney, M.K., and John, R. (2013). Underutilization of influenza vaccine:A test of the health belief model. SAGE Open, 3.","DOI":"10.1177\/2158244013484732"},{"key":"ref_8","unstructured":"Centers for Disease Control and Prevention (CDC) (2018, April 28). People at High Risk of Developing Flu\u2013Related Complications, Available online: https:\/\/www.cdc.gov\/flu\/about\/disease\/high_risk.htm."},{"key":"ref_9","unstructured":"CDC (2018, April 20). Vaccination: Who Should Do It, Who Should Not and Who Should Take Precautions, Available online: https:\/\/www.cdc.gov\/flu\/protect\/whoshouldvax.htm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1016\/S2468-2667(16)30044-5","article-title":"Effect of mass paediatric influenza vaccination on existing influenza vaccination programmes in england and wales: A modelling and cost-effectiveness analysis","volume":"2","author":"Hodgson","year":"2017","journal-title":"Lancet Public Health"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/j.1651-2227.2006.tb02340.x","article-title":"Influenza in children","volume":"95","author":"Heikkinen","year":"2006","journal-title":"Acta Paediatr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/(SICI)1096-9071(200005)61:1<94::AID-JMV15>3.0.CO;2-C","article-title":"Mismatch between the 1997\/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly","volume":"61","author":"Beyer","year":"2000","journal-title":"J. Med. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"15279","DOI":"10.1038\/srep15279","article-title":"H3N2 mismatch of 2014\u201315 northern hemisphere influenza vaccines and head-to-head comparison between human and ferret antisera derived antigenic maps","volume":"5","author":"Xie","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Skowronski, D.M., Chambers, C., De Serres, G., Dickinson, J.A., Winter, A.-L., Hickman, R., Chan, T., Jassem, A.N., Drews, S.J., and Charest, H. (2018). Early season co-circulation of influenza A(H3N2) and B(Yamagata): Interim estimates of 2017\/18 vaccine effectiveness, Canada, January 2018. Eurosurveillance, 23.","DOI":"10.2807\/1560-7917.ES.2018.23.5.18-00035"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Castilla, J., Navascu\u00e9s, A., Casado, I., P\u00e9rez-Garc\u00eda, A., Aguinaga, A., Ezpeleta, G., Pozo, F., Ezpeleta, C., Mart\u00ednez-Baz, I., and Network, P.H.C.S. (2018). Interim effectiveness of trivalent influenza vaccine in a season dominated by lineage mismatched influenza b, northern spain, 2017\/18. Eurosurveillance, 23.","DOI":"10.2807\/1560-7917.ES.2018.23.7.18-00057"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1586\/erv.11.82","article-title":"The future of cell culture-based influenza vaccine production","volume":"10","author":"Perdue","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.3390\/v6083055","article-title":"Virus-vectored influenza virus vaccines","volume":"6","author":"Tripp","year":"2014","journal-title":"Viruses"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Kon, T.C., Onu, A., Berbecila, L., Lupulescu, E., Ghiorgisor, A., Kersten, G.F., Cui, Y.-Q., Amorij, J.-P., and Van der Pol, L. (2016). Influenza vaccine manufacturing: Effect of inactivation, splitting and site of manufacturing. Comparison of influenza vaccine production processes. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0150700"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1128\/CMR.00097-12","article-title":"Traditional and new influenza vaccines","volume":"26","author":"Wong","year":"2013","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/j.vaccine.2017.03.092","article-title":"Efficacy and safety of high-dose influenza vaccine in elderly adults: A systematic review and meta-analysis","volume":"35","author":"Wilkinson","year":"2017","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/infdis\/jiy088","article-title":"Relative vaccine effectiveness of high-dose versus standard-dose influenza vaccines among veterans health administration patients","volume":"217","author":"Mahmud","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Woolthuis, R.G., Wallinga, J., and van Boven, M. (2017). Variation in loss of immunity shapes influenza epidemics and the impact of vaccination. BMC Infect. Dis., 17.","DOI":"10.1186\/s12879-017-2716-y"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2165\/11206860-000000000-00000","article-title":"Live attenuated influenza vaccine (Flumist; Fluenz): A review of its use in the prevention of seasonal influenza in children and adults","volume":"71","author":"Carter","year":"2011","journal-title":"Drugs"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1750-2659.2008.00056.x","article-title":"Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza","volume":"2","author":"Ambrose","year":"2008","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1128\/JCM.38.2.839-845.2000","article-title":"Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial","volume":"38","author":"Cha","year":"2000","journal-title":"J. Clin. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1750-2659.2008.00053.x","article-title":"Flublok, a recombinant hemagglutinin influenza vaccine","volume":"2","author":"Cox","year":"2008","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/2051013615595595","article-title":"Safety, efficacy, and immunogenicity of flublok in the prevention of seasonal influenza in adults","volume":"3","author":"Cox","year":"2015","journal-title":"Ther. Adv. Vaccines"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4161\/hv.22908","article-title":"Correlates of protection to influenza virus, where do we go from here?","volume":"9","author":"Cox","year":"2013","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_29","first-page":"566","article-title":"Influenza: Observations on the recovery of virus from man and on the antibody content of human sera","volume":"16","author":"Andrewes","year":"1935","journal-title":"Br. J. Exp. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1128\/jcm.23.1.66-72.1986","article-title":"Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine","volume":"23","author":"Clements","year":"1986","journal-title":"J. Clin. Microbiol."},{"key":"ref_31","first-page":"767","article-title":"The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses","volume":"70","author":"Hobson","year":"1972","journal-title":"J. Hyg."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Jefferson, T., Di Pietrantonj, C., Rivetti, A., Bawazeer, G.A., Al-Ansary, L.A., and Ferroni, E. (2010). Vaccines for preventing influenza in healthy adults. Cochrane Database Syst. Rev., Cd001269.","DOI":"10.1002\/14651858.CD001269.pub4"},{"key":"ref_33","unstructured":"(1970, January 01). Surveillance of Influenza and Other Respiratory Infections in the Netherlands: Winter 2014\/2015. Available online: https:\/\/www.rivm.nl\/en\/Documents_and_publications\/Scientific\/Reports\/2015\/oktober\/Surveillance_of_influenza_and_other_respiratory_infections_in_the_Netherlands_winter_2014_2015."},{"key":"ref_34","first-page":"21025","article-title":"Low effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014\/15 mid-season results","volume":"20","author":"Pebody","year":"2015","journal-title":"Eurosurveillance"},{"key":"ref_35","first-page":"E28","article-title":"Quadrivalent influenza vaccine: A new opportunity to reduce the influenza burden","volume":"57","author":"Tisa","year":"2016","journal-title":"J. Prev. Med. Hyg."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"European Centre for Disease Prevention and Control (ECDC) (2018). Dominant influenza A(H3N2) and B\/Yamagata virus circulation in EU\/EEA, 2016\/17 and 2017\/18 seasons, respectively. Eurosurveillance, 23, 18-00146.","DOI":"10.2807\/1560-7917.ES.2018.23.13.18-00146"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/infdis\/jir436","article-title":"Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse t-cell responses in young children","volume":"204","author":"Hoft","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"11756","DOI":"10.1128\/JVI.01460-06","article-title":"Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines","volume":"80","author":"He","year":"2006","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1128\/CVI.00397-07","article-title":"Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children","volume":"15","author":"Forrest","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6794","DOI":"10.1016\/j.vaccine.2012.09.018","article-title":"The role of nasal iga in children vaccinated with live attenuated influenza vaccine","volume":"30","author":"Ambrose","year":"2012","journal-title":"Vaccine"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/infdis\/jiw230","article-title":"Live attenuated influenza vaccine in children induces B-cell responses in tonsils","volume":"214","author":"Mohn","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/infdis\/jix165","article-title":"Boosting of cross-reactive and protection-associated t cells in children after live attenuated influenza vaccination","volume":"215","author":"Mohn","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Jefferson, T.O., Rivetti, D., Di Pietrantonj, C., Rivetti, A., and Demicheli, V. (2007). Vaccines for preventing influenza in healthy adults. Cochrane Database Syst. Rev., Cd001269.","DOI":"10.1002\/14651858.CD004879.pub3"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Jefferson, T., Rivetti, A., Harnden, A., Di Pietrantonj, C., and Demicheli, V. (2008). Vaccines for preventing influenza in healthy children. Cochrane Database Syst. Rev., Cd004879.","DOI":"10.1002\/14651858.CD004879.pub3"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1164\/rccm.201411-1988OC","article-title":"Natural T cell-mediated protection against seasonal and pandemic influenza. Results of the flu watch cohort study","volume":"191","author":"Hayward","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"20823","DOI":"10.2807\/1560-7917.ES2014.19.22.20823","article-title":"Uptake and impact of a new live attenuated influenza vaccine programme in england: Early results of a pilot in primary school-age children, 2013\/14 influenza season","volume":"19","author":"Pebody","year":"2014","journal-title":"Eurosurveillance"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1097\/INF.0b013e318168b729","article-title":"Universal influenza vaccination and live attenuated influenza vaccination of children","volume":"27","author":"Glezen","year":"2008","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_48","unstructured":"(2018, April 18). ACIP Votes Down Use of LAIV for 2016\u20132017 Flu Season, Available online: https:\/\/www.cdc.gov\/media\/releases\/2016\/s0622-laiv-flu.html."},{"key":"ref_49","unstructured":"(2018, April 18). Advisory Committee on Immunization Practices (ACIP) Recommends a Preference for Using the Nasal Spray Flu Vaccine, Available online: https:\/\/www.cdc.gov\/media\/releases\/2014\/s0625-acip.html."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"30346","DOI":"10.2807\/1560-7917.ES.2016.21.38.30346","article-title":"Effectiveness of the live attenuated and the inactivated influenza vaccine in two-year-olds\u2014A nationwide cohort study finland, influenza season 2015\/16","volume":"21","author":"Nohynek","year":"2016","journal-title":"Eurosurveillance"},{"key":"ref_51","first-page":"30348","article-title":"Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015\/16 end-of-season results","volume":"21","author":"Pebody","year":"2016","journal-title":"Eurosurveillance"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1093\/cid\/ciw635","article-title":"2014\u20132015 influenza vaccine effectiveness in the United States by vaccine type","volume":"63","author":"Zimmerman","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e955","DOI":"10.1016\/S2214-109X(16)30201-7","article-title":"Efficacy of a russian-backbone live attenuated influenza vaccine among children in senegal: A randomised, double-blind, placebo-controlled trial","volume":"4","author":"Victor","year":"2016","journal-title":"Lancet Glob. Health"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e946","DOI":"10.1016\/S2214-109X(16)30200-5","article-title":"Efficacy of a russian-backbone live attenuated influenza vaccine among young children in Bangladesh: A randomised, double-blind, placebo-controlled trial","volume":"4","author":"Brooks","year":"2016","journal-title":"Lancet Glob. Health"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"30450","DOI":"10.2807\/1560-7917.ES.2017.22.4.30450","article-title":"Live attenuated influenza vaccine effectiveness against hospitalisation due to laboratory-confirmed influenza in children two to six years of age in England in the 2015\/16 season","volume":"22","author":"Pebody","year":"2017","journal-title":"Eurosurveillance"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e20153279","DOI":"10.1542\/peds.2015-3279","article-title":"Seasonal effectiveness of live attenuated and inactivated influenza vaccine","volume":"137","author":"Chung","year":"2016","journal-title":"Pediatrics"},{"key":"ref_57","unstructured":"ECDC (2018, April 18). Seasonal Influenza Vaccines. Available online: https:\/\/ecdc.europa.eu\/en\/seasonal-influenza\/facts\/factsheet."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.4049\/jimmunol.1002090","article-title":"Protective B cell responses to flu\u2014No fluke!","volume":"186","author":"Waffarn","year":"2011","journal-title":"J. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1128\/JVI.01957-06","article-title":"Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines","volume":"81","author":"Sasaki","year":"2007","journal-title":"J. Virol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/infdis\/jit650","article-title":"Virus-specific antibody secreting cell, memory B-cell, and sero-antibody responses in the human influenza challenge model","volume":"209","author":"Huang","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/infdis\/171.6.1595","article-title":"Influenza a virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults","volume":"171","author":"Powers","year":"1995","journal-title":"J. Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd4529","article-title":"Advances in the development of influenza virus vaccines","volume":"14","author":"Krammer","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1128\/JVI.03152-15","article-title":"Design and characterization of a computationally optimized broadly reactive hemagglutinin vaccine for H1N1 influenza viruses","volume":"90","author":"Carter","year":"2016","journal-title":"J. Virol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e01283","DOI":"10.1128\/JVI.01283-17","article-title":"Elicitation of protective antibodies against a broad panel of H1N1 viruses in ferrets preimmune to historical H1N1 influenza viruses","volume":"91","author":"Carter","year":"2017","journal-title":"J. Virol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e01581","DOI":"10.1128\/JVI.01581-17","article-title":"Computationally optimized broadly reactive hemagglutinin elicits hemagglutination inhibition antibodies against a panel of H3N2 influenza virus cocirculating variants","volume":"91","author":"Wong","year":"2017","journal-title":"J. Virol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"16015","DOI":"10.1038\/npjvaccines.2016.15","article-title":"A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice","volume":"1","author":"Nachbagauer","year":"2016","journal-title":"NPJ Vaccines"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1126\/science.aac7263","article-title":"A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen","volume":"349","author":"Impagliazzo","year":"2015","journal-title":"Science"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nm.3927","article-title":"Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection","volume":"21","author":"Yassine","year":"2015","journal-title":"Nat. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"22666","DOI":"10.1038\/srep22666","article-title":"Stalking influenza by vaccination with pre-fusion headless HA mini-stem","volume":"6","author":"Valkenburg","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/nm.3350","article-title":"Cellular immune correlates of protection against symptomatic pandemic influenza","volume":"19","author":"Sridhar","year":"2013","journal-title":"Nat. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/vaccines3020373","article-title":"Influenza vaccination strategies: Comparing inactivated and live attenuated influenza vaccines","volume":"3","author":"Sridhar","year":"2015","journal-title":"Vaccines"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1086\/528804","article-title":"Phenotypic changes in influenza-specific CD8+ T cells after immunization of children and adults with influenza vaccines","volume":"197","author":"He","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ni.3056","article-title":"Antiviral b cell and T cell immunity in the lungs","volume":"16","author":"Chiu","year":"2015","journal-title":"Nat. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1002\/eji.201242504","article-title":"Predominance of heterosubtypic ifn-gamma-only-secreting effector memory t cells in pandemic H1N1 naive adults","volume":"42","author":"Sridhar","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1172\/JCI74565","article-title":"Characterization of pandemic influenza immune memory signature after vaccination or infection","volume":"124","author":"Bonduelle","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_76","unstructured":"Abbas, A.K., Lichtman, A.H., and Pillai, S. (2017). Cellular and Molecular Immunology, Elsevier. [9th ed.]."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.coi.2005.04.010","article-title":"Understanding the generation and function of memory T cell subsets","volume":"17","author":"Lanzavecchia","year":"2005","journal-title":"Curr. Opin. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"6833","DOI":"10.1038\/ncomms7833","article-title":"Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8(+) T cells","volume":"6","author":"Wang","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1128\/jb.89.1.170-174.1965","article-title":"Induction of partial specific heterotypic immunity in mice by a single infection with influenza a virus","volume":"89","author":"Schulman","year":"1965","journal-title":"J. Bacteriol."},{"key":"ref_80","first-page":"297","article-title":"The effect of a previous attack of A1 influenza on susceptibility to A2 virus during the 1957 outbreak","volume":"20","author":"Slepushkin","year":"1959","journal-title":"Bull. World Health Organ."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"660","DOI":"10.4049\/jimmunol.122.2.660","article-title":"Virus specificity of human influenza virus-immune cytotoxic T cells","volume":"122","author":"Biddison","year":"1979","journal-title":"J. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"17040","DOI":"10.1073\/pnas.1212371109","article-title":"Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity","volume":"109","author":"Lee","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"6743","DOI":"10.1128\/JVI.03562-13","article-title":"A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head","volume":"88","author":"Benjamin","year":"2014","journal-title":"J. Virol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.bbrc.2014.09.008","article-title":"A human monoclonal antibody derived from a vaccinated volunteer recognizes heterosubtypically a novel epitope on the hemagglutinin globular head of H1 and H9 influenza a viruses","volume":"452","author":"Boonsathorn","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1073\/pnas.82.6.1785","article-title":"Influenza a virus nucleoprotein is a major target antigen for cross-reactive anti-influenza a virus cytotoxic T lymphocytes","volume":"82","author":"Yewdell","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1084\/jem.165.2.408","article-title":"Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes","volume":"165","author":"Gotch","year":"1987","journal-title":"J. Exp. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.vaccine.2010.12.073","article-title":"CD8+ T cell immunity to 2009 pandemic and seasonal H1N1 influenza viruses","volume":"29","author":"Scheible","year":"2011","journal-title":"Vaccine"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"8682","DOI":"10.1128\/JVI.72.11.8682-8689.1998","article-title":"Human cytotoxic T-lymphocyte repertoire to influenza A viruses","volume":"72","author":"Jameson","year":"1998","journal-title":"J. Virol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Agrati, C., Castilletti, C., Cimini, E., Lapa, D., Quartu, S., Caglioti, C., Lanini, S., Cattoli, G., Martini, F., and Ippolito, G. (2014). Cellular and humoral cross-immunity against two H3N2V influenza strains in presumably unexposed healthy and hiv-infected subjects. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0105651"},{"key":"ref_90","first-page":"3478","article-title":"Memory t cells established by seasonal human influenza a infection cross-react with avian influenza a (H5N1) in healthy individuals","volume":"118","author":"Lee","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1073\/pnas.1322229111","article-title":"Preexisting CD8+ T-cell immunity to the H7N9 influenza A virus varies across ethnicities","volume":"111","author":"Grant","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"24402","DOI":"10.1038\/srep24402","article-title":"Long-lasting cross-protection against influenza A by neuraminidase and M2E-based immunization strategies","volume":"6","author":"Schotsaert","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/mt.2013.284","article-title":"Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza A antigens","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciq015","article-title":"Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza a vaccine, MVA-NP+M1","volume":"52","author":"Berthoud","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1128\/CVI.00315-12","article-title":"Intranasal vaccination with replication-defective adenovirus type 5 encoding influenza virus hemagglutinin elicits protective immunity to homologous challenge and partial protection to heterologous challenge in pigs","volume":"19","author":"Braucher","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2174\/156652311795684731","article-title":"MVA and NYVAC as vaccines against emergent infectious diseases and cancer","volume":"11","author":"Gomez","year":"2011","journal-title":"Curr. Gene Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/mt.2013.162","article-title":"Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1074-7613(01)00126-1","article-title":"Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo","volume":"14","author":"Schiavoni","year":"2001","journal-title":"Immunity"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1586\/erv.10.140","article-title":"Adjuvants: No longer a \u2018dirty little secret\u2019, but essential key players in vaccines of the future","volume":"10","author":"Arakawa","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.coviro.2011.08.002","article-title":"Influenza virus vaccines: Lessons from the 2009 H1N1 pandemic","volume":"1","author":"Broadbent","year":"2011","journal-title":"Curr. Opin. Virol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/vaccines3020320","article-title":"Vaccine adjuvants: From 1920 to 2015 and beyond","volume":"3","author":"Preiss","year":"2015","journal-title":"Vaccines"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.vaccine.2011.01.011","article-title":"Adjuvant system AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity","volume":"29","author":"Morel","year":"2011","journal-title":"Vaccine"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.4161\/hv.21265","article-title":"Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age","volume":"8","author":"Vesikari","year":"2012","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"37229","DOI":"10.1038\/srep37229","article-title":"Investigating the effect of AS03 adjuvant on the plasma cell repertoire following PH1N1 influenza vaccination","volume":"6","author":"Galson","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.vaccine.2016.12.011","article-title":"Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis","volume":"35","author":"Domnich","year":"2017","journal-title":"Vaccine"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1056\/NEJMoa061850","article-title":"Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines","volume":"355","author":"Ohmit","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1001\/jama.284.13.1655","article-title":"Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial","volume":"284","author":"Bridges","year":"2000","journal-title":"JAMA"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJM199510053331401","article-title":"The effectiveness of vaccination against influenza in healthy, working adults","volume":"333","author":"Nichol","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(18)30942-5","article-title":"Addressing decreasing vaccine coverage in the EU","volume":"391","author":"Lancet","year":"2018","journal-title":"Lancet"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"King, C., and Leask, J. (2017). The impact of a vaccine scare on parental views, trust and information needs: A qualitative study in Sydney, Australia. BMC Public Health, 17.","DOI":"10.1186\/s12889-017-4032-2"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e1218","DOI":"10.1542\/peds.2013-3707","article-title":"Effectiveness of trivalent flu vaccine in healthy young children","volume":"133","author":"Blyth","year":"2014","journal-title":"Pediatrics"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Nohynek, H., Jokinen, J., Partinen, M., Vaarala, O., Kirjavainen, T., Sundman, J., Himanen, S.L., Hublin, C., Julkunen, I., and Olsen, P. (2012). AS03 adjuvanted ah1n1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0033536"},{"key":"ref_114","unstructured":"(2018, April 20). The MPA Investigates Reports of Narcolepsy in Patients Vaccinated with Pandemrix. Available online: https:\/\/lakemedelsverket.se\/english\/All-news\/NYHETER-2010\/The-MPA-investigates-reports-of-narcolepsy-in-patients-vaccinated-with-Pandemrix\/2010."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.5665\/sleep.5752","article-title":"Risk of narcolepsy after AS03 adjuvanted pandemic A\/H1N1 2009 influenza vaccine in adults: A case-coverage study in england","volume":"39","author":"Stowe","year":"2016","journal-title":"Sleep"},{"key":"ref_116","first-page":"20789","article-title":"Investigation of an association between onset of narcolepsy and vaccination with pandemic influenza vaccine, Ireland April 2009\u2013December 2010","volume":"19","author":"Barret","year":"2014","journal-title":"Eurosurveillance"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Partinen, M., Saarenp\u00e4\u00e4-Heikkil\u00e4, O., Ilveskoski, I., Hublin, C., Linna, M., Ols\u00e9n, P., Nokelainen, P., Al\u00e9n, R., Wallden, T., and Espo, M. (2012). Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0033723"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"f794","DOI":"10.1136\/bmj.f794","article-title":"Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A\/H1N1 2009 influenza vaccine: Retrospective analysis","volume":"346","author":"Miller","year":"2013","journal-title":"Br. Med. J."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1212\/WNL.0000000000000987","article-title":"Narcolepsy and influenza A(H1N1) pandemic 2009 vaccination in the United States","volume":"83","author":"Duffy","year":"2014","journal-title":"Neurology"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.vaccine.2017.12.019","article-title":"How close are countries of the who european region to achieving the goal of vaccinating 75% of key risk groups against influenza? Results from national surveys on seasonal influenza vaccination programmes, 2008\/2009 to 2014\/2015","volume":"36","author":"Jorgensen","year":"2018","journal-title":"Vaccine"},{"key":"ref_121","unstructured":"CDC (2018, April 20). Rapid Influenza Diagnostic Tests, Available online: https:\/\/www.cdc.gov\/flu\/professionals\/diagnosis\/clinician_guidance_ridt.htm."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.chom.2015.10.003","article-title":"The quest for a universal flu vaccine: Headless HA 2.0","volume":"18","author":"Krammer","year":"2015","journal-title":"Cell Host Microbe"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/infdis\/jiu654","article-title":"Longevity of B-cell and T-cell responses after live attenuated influenza vaccination in children","volume":"211","author":"Mohn","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/infdis\/jiu458","article-title":"Live attenuated and inactivated influenza vaccines in children","volume":"211","author":"Ilyushina","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/S2468-2667(17)30004-X","article-title":"Have you herd? Indirect flu vaccine effects are critically important","volume":"2","author":"Fisman","year":"2017","journal-title":"Lancet Public Health"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/6\/2\/32\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:06:04Z","timestamp":1760195164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/6\/2\/32"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,26]]},"references-count":125,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,6]]}},"alternative-id":["vaccines6020032"],"URL":"https:\/\/doi.org\/10.3390\/vaccines6020032","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,26]]}}}